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Abstract: BACKGROUND AND AIMS Psoriasis affects more than 3% of the general population and is
associated with an increased risk of premature cardiovascular events and death. We assessed the prognos-
tic role of coronary flow reserve (CFR) as a marker of coronary microvascular function in psoriasis patients
asymptomatic for cardiovascular disease. METHODS We retrospectively analyzed 153 prospectively col-
lected patients affected by psoriasis (123 male; age 36 ± 8 years) without cardiovascular disease. CFR
in the left anterior descending coronary artery was detected by transthoracic Doppler echocardiography,
at rest, and during adenosine infusion. CFR was the ratio of hyperemic to resting diastolic flow velocity.
CFR ฀2.5 was the cut off to define the presence of coronary microvascular dysfunction (CMD). RESULTS
CMD was present in 23 patients (15%). Multivariable logistic regression analysis showed that CMD was
associated with severe psoriasis (OR 3.1, p = 0.03), psoriatic arthritis (OR 2.9, p = 0.03), hypertension
(OR 4.1, p = 0.009), and time elapsing since psoriasis diagnosis >6 years (OR 1.9, p = 0.03). Patients
with CFR ฀2.5 had a lower survival free from events (p < 0.0001). CONCLUSIONS In psoriasis patients,
CFR may be a reliable prognostic marker for cardiovascular event-free survival and may help identify
patients at higher risk of developing cardiovascular complications. Whether novel biologic therapies able
to reduce skin disease will improve CMD and prognosis in these patients needs to be further studied,
prospectively.
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Abstract: Background and Aims: Psoriasis affects more than 3% of the 
general population and is associated with an increased risk of premature 
cardiovascular events and death. We assessed the prognostic role of 
coronary flow reserve (CFR) as a marker of coronary microvascular 
function in psoriasis patients asymptomatic for cardiovascular disease. 
Methods: We retrospectively analyzed 153 prospectively collected patients 
affected by psoriasis (123 male; age, 36±8 years) without cardiovascular 
disease. CFR in the left anterior descending coronary artery was detected 
by transthoracic Doppler echocardiography, at rest, and during adenosine 
infusion. CFR was the ratio of hyperemic to resting diastolic flow 
velocity. CFR ≤2.5 was the cut off to define the presence of coronary 
microvascular dysfunction (CMD).  
Results: CMD was present in 23 patients (15%). Multivariable logistic 
regression analysis showed that CMD was associated with severe psoriasis 
(OR 3.1, p=0.03), psoriatic arthritis (OR 2.9, p=0.03), hypertension (OR 
4.1, p=0.009), and time elapsing since psoriasis diagnosis >6 years (OR 
1.9, p=0.03). Patients with CFR ≤2.5 had a lower survival free from 
events (p<0.0001).  
Conclusions: In psoriasis patients, CFR may be a reliable prognostic 
marker for cardiovascular event-free survival and may help to identify 
patients at higher risk of developing cardiovascular complications. 
Whether novel biologic therapies able to reduce skin disease will improve 









 This study analyzed the prognostic role of coronary flow reserve in psoriasis. 
 153 psoriatic patients without cardiovascular disease were included. 
 Coronary microvascular dysfunction was present in 15% of patients. 





































































Long-term prognostic value of coronary flow reserve in psoriasis patients 
 
 
Stefano Piaserico, MD, PhD
a1
; Elena Osto, MD, PhD
b,c1





; Laura De Michieli, MD
d
; Irene Zanetti, MD
d
; Sabino Iliceto, MD
d






Dermatology Unit, Department of Medicine, 
b 
University Heart Center and 
c
Institute of Clinical 
Chemistry, University Hospital Zurich, Zurich, Switzerland, Department of Cardiac, Thoracic, 
Vascular Sciences and Public Health, University of Padova, Padova, Italy,
e
Clinical Cardiology, 





Corresponding author and person to whom reprint requests should be addressed: 
1
 these authors contributed equally. 
 
*Francesco Tona, MD, PhD 
Department of Cardiac, Thoracic, Vascular Sciences and Public Health 
University of Padova, Padova, Italy 
Phone: +390498211844 




Running title: Coronary microcirculation in psoriasis 
  






































































Background and Aims: Psoriasis affects more than 3% of the general population and is associated 
with an increased risk of premature cardiovascular events and death. We assessed the prognostic 
role of coronary flow reserve (CFR) as a marker of coronary microvascular function in psoriasis 
patients asymptomatic for cardiovascular disease. 
Methods: We retrospectively analyzed 153 prospectively collected patients affected by psoriasis 
(123 male; age, 36±8 years) without cardiovascular disease. CFR in the left anterior descending 
coronary artery was detected by transthoracic Doppler echocardiography, at rest, and during 
adenosine infusion. CFR was the ratio of hyperemic to resting diastolic flow velocity. CFR ≤2.5 was 
the cut off to define the presence of coronary microvascular dysfunction (CMD).  
Results: CMD was present in 23 patients (15%). Multivariable logistic regression analysis showed 
that CMD was associated with severe psoriasis (OR 3.1, p=0.03), psoriatic arthritis (OR 2.9, 
p=0.03), hypertension (OR 4.1, p=0.009), and time elapsing since psoriasis diagnosis >6 years (OR 
1.9, p=0.03). Patients with CFR ≤2.5 had a lower survival free from events (p<0.0001).  
Conclusions: In psoriasis patients, CFR may be a reliable prognostic marker for cardiovascular 
event-free survival and may help to identify patients at higher risk of developing cardiovascular 
complications. Whether novel biologic therapies able to reduce skin disease will improve CMD and 
prognosis in these patients needs to be further studied, prospectively.  
 








































































Patients affected by psoriasis, similarly to other chronic inflammatory systemic immune-mediated 
diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic 
sclerosis (SSc), suffer from increased cardiovascular morbidity and mortality due to premature and 
accelerated atherosclerosis (1).  
Systemic chronic inflammation is regarded as a major causal mechanism leading to 
atherosclerosis-driven clinical and subclinical coronary artery disease in patients with psoriasis and 
other immune-mediated diseases. (2,3).  
Recent positive results obtained by monoclonal antibodies against interleukin (IL)-1b in secondary 
prevention of cardiovascular events in patients with coronary artery disease and residual 
inflammatory risk, further support inflammation as a therapeutic target in atherosclerosis (4). 
Indeed, in patients with severe psoriasis, biologic therapies (i.e. anti TNF, anti-IL-12/23 and anti- 
IL-17) were associated with favorable modulation of coronary plaque characteristics on the short 
term and anti TNF decreased risk for myocardial infarction over a longer period of treatment 
(5,6). 
Coronary microvascular dysfunction (CMD) describes a disease entity common to various clinical 
situations in which a reduced coronary flow reserve (CFR) (i.e. the ratio between blood flow during 
maximal coronary vasodilation and resting flow) along with evidence of myocardial ischaemia are 
not secondary to epicardial coronary artery stenosis (7). We previously reported in young patients 
with psoriasis, without traditional cardiovascular risk factors or angiographic evidence for 
coronary artery disease, higher prevalence of CMD detected by CFR measured by transthoracic 
Doppler echocardiography (TDE). In these patients, the degree of CMD was directly correlated to 




































































improved by anti-TNF therapy, which is  commonly considered as the first line biologic agent for 
the treatment of psoriasis (9).  
Emerging data documents that CMD, despite the absence of obstructive CAD, is not a benign 
condition. Indeed, in patients with systemic immune-mediated diseases like SSc, CMD is 
associated to higher risk of adverse cardiovascular outcomes (10).  
The starting hypothesis of our work is that even in patients with psoriasis the CMD may play a 
prognostic role. Consequently, the aim and the novelty of the present study was to characterize in 
patients with moderate-to-severe psoriasis the cardiovascular long-term prognostic value of 
impaired CFR detected by TDE, as a cost-effective tool to risk-stratify young patients with CMD 
without hemodynamically significant stenosis as detected by coronary multi-slice computed 
tomography [MSCT].  
 
Material and Methods 
This study is a retrospective analysis of prospectively collected data at a single center. We enrolled 
153 consecutive patients affected by moderate-to-severe psoriasis (123 male; mean age, 36±8 
years, range 18-50), recruited between January 2009 and December 2015. All patients had a 
diagnosis of moderate to severe psoriasis since at least 12 months, stable plaque psoriasis since at 
least 2 months before screening. Patients were included if they met the following inclusion 
criteria: available CFR and MSCT evaluation, age <50 years, no symptoms or history of 
cardiovascular disease. The following risk factors for coronary artery disease were assessed at the 
time of CFR evaluation: hypertension, diabetes mellitus, hypercholesterolemia, smoking, high-
sensitive C-reactive protein (hsCRP), family history of heart disease, body mass index (BMI). For 
risk factors definition see Supplementary Material online. Exclusion criteria were high blood 




































































men and >120 μmol/L in women), or hepatic disease and malignant or infectious disease. The 
activity of psoriasis was determined using the validated disease-specific activity index PASI. 
Psoriasis Area Severity Index (PASI) evaluation 
The body is divided into four regions comprising the head, upper extremities, trunk, and lower 
extremities. In each of these areas, the fraction of total surface area affected is graded on a 0–6 
scale (0 for no involvement up to 6 for greater than 90% involvement). The various body regions 
are weighted to reflect their respective proportion of body surface area. The composite PASI score 
is then calculated by multiplying the sum of the individual-severity scores for each region by the 
weighted area-of-involvement score for that respective region, and then summing the four 
resulting quantities. The highest potential PASI score is 72; the lowest is 0. PASI scores are nearly 
continuous, with 0.1 increments within these values. PASI 5-10 defined moderate psoriasis, 
PASI>10 defined a severe psoriasis.  
Echocardiography methods and coronary flow velocity reserve assessment 
Transthoracic Doppler echocardiography was performed with a commercially available ultrasound 
system (Vivid 7, GE Medical System, Inc., Hortem, Norway). Doppler echocardiography and CFR 
assessment has been previously detailed (11-14). A CFR≤2.5 was considered abnormal (15), and 
the population was dichotomized according to this cutoff. 
MSCT coronary angiography protocol and interpretation 
Patients with abnormal CFR underwent to MSCT coronary angiography to exclude epicardial 
significant CAD and to measure calcium score. Coronary MSCT was performed using a 64-slice 
dual-source scanner (Definition, Siemens Medical System, Forchheim, Germany). MSCT protocol 
and interpretation has been previously detailed (16). 
Adverse outcomes during follow-up  




































































events (MACE). During a follow up performed every 3 months, records of patients reporting an 
event were reviewed by an events committee blinded to CFR evaluation and tabulated as death, 
nonfatal myocardial infarction (MI), nonfatal stroke; and hospital stay for congestive heart failure 
(CHF), angina, and other vascular events. Those with death, nonfatal MI, nonfatal stroke, or CHF 
hospital stay were categorized as having MACE. Angina and myocardial infarctions were defined 
by ESC guidelines (17,18).  
Statistical analysis 
Continuous variables with no/mild skew were presented as mean ± SD; skewed measures were 
represented as median
 
with first and third quartiles (Q1-Q3). Discrete variables were summarized 
as frequencies and percentages. The distribution of the data was analysed with a 1-sample 
Kolmogorov-Smirnov test. Categorical variables were compared by the 2 test or the Fisher exact 
test as appropriate. Continuous data were compared by use of the 2-tailed paired or unpaired t 
test (for normally distributed data sets) or the Mann-Whitney U or Wilcoxon signed-rank test (for 
skewed variables). Stepwise logistic regression analysis was used to model normal versus 
abnormal CFR (2.5) and risk factors. Baseline characteristics were chosen for entry into 
multivariable models on the basis of their discrimination between normal and abnormal CFR and 
on unadjusted association with CFR ≤2.5 of p ≤0.1. In order to account for possible modulator 
effects, we then forced all other variables from Table 1 into the model, one at a time. A 
combination of forward and backward selection procedures was used to aid in determining the 
best model of factors independently associated with CFR≤2.5. Median values for age, severity of 
psoriasis and duration of psoriasis were selected as a cut point for simplicity in the multivariable 
analysis. Summary statistics for the regression models included the c-statistic (a measure of 
association of predicted probabilities and observed prevalence of a binary outcome) and R
2
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regression analysis was also used to model event versus non event (as dependent variable) and 
CMD. Event-free survival curves were traced by use of the Kaplan-Meier method and compared by 
log-rank test. All tests were two-sided and statistical significance was accepted if the null 
hypothesis could be rejected at p<0.05. Data were analyzed with SPSS software version 24.0 
(Chicago, SPSS, Inc., Chicago, Illinois). The authors had full access to the data and take full 
responsibility for its integrity. All authors have read and agree to the manuscript as written. The 
study protocol was reviewed and approved by the institutional ethical committee. All participants 
gave their written informed consent to participate in the study. 
Sample size determination 
Although the study sample size was limited, a priori power calculations based on a one tailed t-test 
to obtain a power of 0.80, a significance level of 0.05 and an effect size based on published values 
of standard deviations and MACE incidence in moderate-to-severe psoriasis, would estimate that 
with 1:1 matching of patients without CMD and patients with CMD and an assumed relative 
survival free from MACE of 0.8 in the group with CMD, we would need approximately 34 patients 
in each group to show a difference.  
A post-hoc power analysis (assuming =0.05) estimated that with 130 patients without CMD and 
23 patients with CMD, with an event incidence of 0% in patients without CMD and 21% in patients 




There were no adverse reactions to adenosine. The baseline characteristics of the 153 patients are 
summarized in Table 1. The mean duration of follow-up was 5.53  2.42 years (range, 0.6 to 9.4 




































































hypercholesterolemia, 52 (33.9%) current cigarette smokers and 36 (23.5%) with a family history 
of heart disease. No patient was diabetic. Mean BMI was 26.3±4. Total cholesterol was 
194±43mg/dL, and triglycerides were 110± 61mg/dL. In the whole study group CFR was 3.16±0.79. 
On individual patient analysis, CFR was >2.5 in 130 patients (84.9%), and ≤2.5 in 23 patients 
(15.1%). The presence of epicardial artery stenosis was excluded by MSCT in all of 23 patients with 
CFR≤2.5 and Calcium Score was<10 in all patients with CFR≤2.5. For hemodynamic parameters 
during CFR evaluation see the Supplementary results online. 
Characteristics of patients with CMD (CFR≤2.5) 
Patients with CMD were older (40±9 vs 37±7 years, p=0.03), had a greater severity of psoriasis 
(PASI 18 [11-20] vs 13 [11-15], p=0.02), a longer time elapsing since psoriasis diagnosis (17 [10-26] 
vs 14 [9-21] years, p=0.03), and more frequently had psoriatic arthritis (52.4% vs 29.3%, p=0.03), 
hypertension (38.1% vs 12.0%, p=0.003) and family history of heart disease (42.9% vs 20.3%, 
p=0.024) (Table 1). 
Factors associated with CMD (CFR≤2.5)  
In unadjusted logistic regression analysis, the significant or marginally significant (p≤0.1) risk 
factors were age (p=0.03), time elapsing since psoriasis diagnosis >6 years (p=0.03), hypertension 
(p=0.002), PASI >10 (p=0.09), and PsA (p=0.1). Factors independently associated with CMD are 
summarized in Table 2. When modelled using a stepwise regression and adjusting for baseline 
differences and predictors at unadjusted logistic regression analysis, the factors independently 
associated with CMD were time elapsing since psoriasis diagnosis >6 years and hypertension 
(p=0.03 and p=0.007, respectively) (Table 2). The inclusion of heart rate-pressure product did not 
greatly affect the model and no other clinical characteristic entered as a significant covariate. To 
exclude the modulating effect of other variables, we also added variables marginally significant in 




































































with CMD, but their addition to the model did not significantly affect the relationship between 
CMD and hypertension or time elapsing since psoriasis diagnosis >6 years (Table 2).  When other 
conditions (current smoking, BMI, and total cholesterol) were forced into the model (potentially 
overfitting it), time elapsing since psoriasis diagnosis >6 years and hypertension remained 
significantly associated with CMD (p=0.03 and p=0.02, respectively) (model 3).  
Major adverse cardiac events 
A total of 5 patients experienced a MACE. All of them had a CFR≤2.5 at the beginning of the study. 
Three patients experienced a type 1 myocardial infarction. One vessel critical epicardial stenosis 
was diagnosed in 2 patients, which were treated with percutaneous revascularization. Three 
vessels critical epicardial stenosis was diagnosed in only one patient treated with surgical 
revascularizazion. Epicardial coronary arteries were normal in the other 2 patients with MINOCA 
(myocardial infarction with non-obstructive coronary arteries) (Table 3) (19). 
The baseline features of patients with and without cardiovascular events are shown in Table 4. 
Patients with cardiovascular events were older (p=0.04), had an higer PASI (p=0.001), longer time 
elapsing since psoriasis diagnosis (p=0.04), and higher prevalence of hypertension (p=0.002). 
Cardiological therapy and specific therapy for psoriasis were comparable in the two groups. 
Hyperemic (during adenosine infusion) diastolic coronary flow and CFR were lower in patients with 
MACE (57 [48-61] vs 70 [60-80] cm/s, 2.1±0.2 vs 3.1±0.7; p=0.03 and p=0.001, respectively). CMD 
was present in 18 (12.2%) patients without MACE and in all 5 (100%) patients with MACE 
(p<0.0001). Figure 1 shows the cumulative survival free from cardiovascular events according to 
the presence of CMD. The prevalence of hypertension was the only difference between patients 
with CMD and MACE and patients with CMD without MACE (80% vs 27.8%, p=0.03). PASI tended 
to be higher in patients with CMD and MACE compared with patients with CMD without MACE 








































































In this study, we found CFR to be reduced in 15% of asymptomatic psoriasis patients without 
evidence of epicardial coronary stenosis. Of note, our study patients were relatively young (mean 
age 36 years) and with a rather low prevalence of traditional CV risk factors. This is in agreement 
with previous studies that reported abnormal CFR in patients with psoriasis or other systemic 
inflammatory diseases (such as SLE, ankylosing spondylitis, RA, inflammatory bowel disease) with 
normal coronary arteries, indicating that microcirculation may be affected before the occurrence 
of coronary atherosclerosis (1,8). 
Most importantly, CFR was found to predict MACE-free survival in our psoriasis patients. Patients 
with CMD had significantly worse outcome than patients without CMD. Twenty one percent of 
psoriasis patients with an impaired CFR developed a MACE. This is an impressive outcome 
considering the age of our study patients, ranging from 18 to 50 years. 
Patients affected by severe psoriasis show increased risk of premature CV events and death (20-
22). Traditional CV risk factors appear to contribute to cardiovascular events development in 
patients with severe psoriasis. However, the increased risk noted in this common inflammatory 
condition is not completely captured by traditional risk assessment, and persists beyond 
adjustment for these factors. The analysis of the General Practice Research Database showed that 
patients with severe psoriasis had a 53% (23) and 57% (20) increased risk for major adverse 
cardiac events and CV mortality, respectively, after adjusting for age, gender, diabetes, 




































































As inflammation is a critical component of atherosclerosis pathophysiology, chronic inflammation 
in psoriasis patients may play a significant role in the shared mechanisms driving accelerated-
atherosclerosis. During a psoriasis flare, there are more than 1 billion immune cells activated 
within the body. Psoriasis is characterized by increased pro-inflammatory cytokine levels and 
activation of myeloid dendritic cells, neutrophils, and Th cells (mostly Th17). T cells secrete 
intermediates (e.g., IL-17F, IL-17A, and IL-22), which, in turn, activate keratinocytes and further 
stimulate the production of pro-inflammatory cytokines. IL-17A, IL-1, and TNF- play also a role in 
atherosclerosis by driving cell-mediated immunity. 
The prognostic value of an impaired CFR has been well demonstrated in several groups of patients, 
even without coronary artery disease (24-26). In fact, impaired CFR might not only represent the 
extent of disease in conductance vessels but might also be related to pure microvascular 
vasomotor dysfunction, because in the absence of hemodynamically significant stenosis maximal 
increase of blood flow is predominantly determined by resistance vessels of the coronary 
microcirculation. Intriguingly, a reduced CFR has been showed to predict a worse cardiovascular 
prognosis also in asymptomatic patients with diabetes (27) or systemic sclerosis (10). In our study 
patients, CFR impairment was not associated to significant coronary artery disease. These findings 
are suggestive of CMD, which may represent an early marker of accelerated coronary 
atherosclerosis and contribute to the increased cardiovascular morbidity and mortality in these 
patients. In keeping with this, our study suggests that CMD may precede, at least in some cases, 
the onset of an epicardial disease, susceptible of percutaneous or surgical revascularization. 
Indeed, coronary arteries were normal at MSCT at the time of CFR assessment in all our patients 
with type 1 myocardial infarction.  
Systemic inflammation has been shown to be an important risk factor for CMD, similarly to 




































































(1, 28-31). In our population, a blunted CFR was associated with a severe psoriasis and the 
presence of psoriatic arthritis, both associated with a higher systemic inflammatory burden (32, 
33). In this context, a psoriasis/psoriatic arthritis-specific element appears to contribute to the 
CMD and the increased cardiovascular risk associated with psoriasis, although the precise nature 
of this remains to be determined. Soluble factors including increased levels of the pro-
inflammatory cytokines, TNF- and IL-17, may be important. TNF- may impair the activation of 
endothelial nitric oxide synthase (eNOS), degrade eNOS mRNA, alter vasomotor function acting on 
vascular smooth muscle cells and induces oxidative stress by increasing the production of reactive 
oxygen species (34). Some studies reported that also in healthy individuals circulating levels of 
several different pro-inflammatory cytokines, in particular IL-6 and TNF-, are associated with risk 
of CV outcomes in an approximately log-linear manner (35, 36). IL-6 is able to promote 
differentiation of naive Th cells into Th17 cells, that represent the most important pathogenic cell 
in psoriasis lesions development (37). In the last years, inhibitors of IL-17 and TNF- have become 
available in the treatment of psoriasis and other inflammatory diseases. Non-randomized data 
from biological registries suggest that TNF- blocking therapy could reduce CV risk in patients 
affected by rheumatological and dermatological diseases (38). 
We have recently reported that CMD improves after treatment with TNF- inhibitors in patients 
with established psoriasis (9). Therefore, it is plausible that chronic inflammation represents the 
linking mechanism between psoriasis, CMD and increased CV risk, and that anti-inflammatory 
treatment may help to reduce this risk. 
The results of the present study have a potential impact in the management of patients with 
psoriasis. Cardiovascular risk stratification of patients with psoriasis remains a difficult clinical 
problem.  Since psoriasis patients face an increased risk of coronary artery disease, it is important 




































































morbidity and mortality. Screening by noninvasive Doppler-derived CFR might represent a 
valuable, safe and inexpensive tool for assessing the presence and prognostic effect of macro- and 
microvascular disease in patients with psoriasis. In our opinion no further cardiological deepening 
might be justified for patients with CFR >2.5, because of their low risk for future cardiac events. On 
the contrary, strict follow-up should be considered for patients with CFR≤2.5. In these higher risk 
patients, an aggressive strategy, including the careful management of conventional CV risk factors, 
seems to represent the logical approach. Optimizing cardiovascular prevention and care in this 
patient population should involve close liaison between cardiologists and dermatologists. 
Furthermore, the control of psoriasis and its related systemic inflammation using powerful drugs 
blocking major drivers of skin and vascular inflammation (namely TNF- and IL-17), may eventually 
impart benefits toward overall CV risk. Recently, CANTOS study showed that IL-1 inhibition by 
Canakinumab inhibition given once every three months among patients with a prior myocardial 
infarction and a persistent increase in C-reactive protein reduced the hazard ratio for 
cardiovascular events of 15% compared with placebo (4).  
Further studies need to provide more insights on the duration of improvement of CMD obtained 
with appropriate psoriasis therapy during time and the real impact of a recover of blunted CFR on 
future cardiovascular outcomes in these patients. 
As outlined above, the mechanism of atherogenesis as well as the coronary microvascular 
dysfunction is mainly considered an inflammatory process. Supporting this view, many studies 
have shown that also a low-grade systemic inflammation leads to an increased risk of 
cardiovascular events.  Diet is one of the most important factors that can affect the inflammatory 
process and oxidative stress, and it could actually represent a good and relatively easy point of 
intervention to reduce the risk of cardiovascular disease. Indeed, some foods may have a 




































































(39). For example, the Western diet, mainly characterized by meat consumption, is positively 
associated with inflammatory biomarkers, while the Mediterranean diet has been shown to 
reduce some inflammatory biomarkers. Several studies have evaluated the role of individual 
nutrients on psoriasis (40). In particular, the greater adherence to the Mediterranean diet is 
associated with a lesser severity of psoriasis, both objective and subjective, independently of the 
modalty of treatment and the presence of obesity, and lower levels of C-reactive protein (41).  In 
this context, we are not able to exclude the possible effect of the diet on the microcirculatory 
function in our patients. However, this influence seems unlikely as our patients' diet did not differ 
significantly and our patients also came largely from the same geographical area and not from 
areas with different eating habits. 
Some important limitations need to be taken into account in the present study.  It is a 
retrospective study, with a small sample size and with few events. The small sample size and few 
events did not allow us to perform a survival multivariable analysis and mostly error and non-
reproducible may also occur. Even though caution must be applied while extrapolating our results, 
we believe our sample might be representative of the region since our medical center is a high 
volume reference for psoriasis and CFR assessment. There may be an inherent selection bias 
because of its nonrandomized design. A large-scale randomized controlled trial would be ideal. 
Further larger trials with larger patient populations should be performed to confirm our data and, 
more importantly, to establish the potential beneficial role of reversing CMD by interventional 
strategies for long-term atherosclerotic disease progression. 
Clinical perspective 
Our findings confirm a novel role of coronary microcirculation in the pathophysiology of 
cardiovascular disease in severe psoriasis. CFR by TDE may be a noninvasive, simple, and objective 




































































patients. Moreover, our data may improve the management and treatment of psoriasis in its 
cardiac asymptomatic initial phase and may explain why the disease is associated with increased 
cardiovascular morbidity and risk, although molecular mechanisms involved need to be further 
investigated. 
Conclusions 
The results of the present study provide evidence that CMD is associated with a greater severity of 
psoriasis and the presence of psoriatic arthritis, both increasing the burden of inflammation, and 
hypertension. Moreover, our study suggests that psoriasis patients with CMD carry a higher risk of 
cardiovascular events over a long-term follow up. These results not only provide a rationale for 
using CFR determination for cardiovascular risk assessment in psoriasis patients, but also reinforce 
the concept of systemic inflammation as a prognostic parameter for CMD and, eventually, for 
adverse long-term CV outcome. Whether novel biologic therapies able to reduce skin disease will 
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Table 1. Clinical characteristics of the study population, stratified by presence or absence of coronary microvascular dysfunction (CMD; 
CFR≤2.5)  
 All patients (n=153) 
CMD present (CFR 2.0±0.4, 
range 1.2-2.5; n=23) 
CMD absent (CFR 3.3±0.6, 
range 2.6-6.3; n=130) 
p 
Age, years 36±8 40±9 36±7 0.03 
Males, n (%) 122 (79.7) 20 (87) 102 (78.5) 0.5 
PASI 15 [11-20] 18 [11-20] 13 [11-15] 0.02 
time elapsing since psoriasis diagnosis, years 16 [10-22] 17 [10-26] 14 [9-21] 0.03 
Presence of PsA, n (%) 50 (32.6) 11 (47.8) 39 (30) 0.03 
BMI, Kg/m
2
 26.39±4 25.76±3.91 26.48±4.01 0.4 
Hypertension, n (%) 24 (15.8) 9 (39.1) 15 (11.6) 0.003 
Family history of heart disease, n (%) 36 (23.5) 10 (43.4) 26 (20) 0.02 
Current smoking, n (%) 52 (33.9) 8 (34.8) 44 (33.8) 0.6 
Previous smoking, n (%) 43 (28.1) 5 (21.7) 38 (29.2) 0.7 
SBP, mmHg 121±14 124±15 121±14 0.5 
DBP, mmHg 76±11 75±7 76±12 0.6 
Total cholesterol, mg/dL 194.74±43.17 203.56±42.43 193.31±43.31 0.3 
Triglycerides, mg/dL 110.53±61.96 113.50±80.61 110.05±58.80 0.8 
hsCRP, mg/L 2.39±3.26 3.24±1.81 2.31±3.37 0.4 
BMI, Body Mass Index; CFR, coronary flow reserve; CMD, coronary microvascular dysfunction; hsCRP, high sensitive-C reactive protein; PASI, 
Psoriasis Area Severity Index; PsA, psoriatic arthritis. DBP, diastolic blood pressure; SBP, systolic blood pressure. Data are presented as mean ± SD  
Table 1
Table 2: Factors independently associated with coronary microvascular dysfunction (CFR2.5)  
 OR 95% CI p 
Model 1: obtained by stepwise logistic regression (C-statistic = 0.80; R
2
 = 0.62)    
      Age  1 0.9-1.1 0.6 
      Time elapsing since psoriasis diagnosis>6 years 2.02 1.4-5.4 0.03 
      Hypertension 4.4 1.4-13.4 0.007 
Model 2: obtained also including variables marginally significant (p≤0.1) (C-statistic = 0.78; R2 = 0.61)     
      Age  1 0.8-1.09 0.8 
      Time elapsing since psoriasis diagnosis >6 years 1.9 1.2-4.6 0.03 
      Hypertension 4.1 1.3-12.1 0.009 
      PASI>10 3.1 1.1-8.7 0.03 
      PsA 2.9 1.07-8.1 0.03 
Model 3: obtained forcing other variables (C-statistic = 0.87; R
2
 = 0.70)    
      Age 1 0.8-1.06 0.7 
      Time elapsing since psoriasis diagnosis >6 years 1.7 1.2-3.8 0.03 
      Hypertension 3.6 1.2-9.1 0.02 
      PASI>10 1.8 1.3-6.2 0.04 
      PsA 1.8 1.04-6.1 0.07 
CI indicates confidence interval; OR, odds ratio. The following variables were considered by the stepwise procedure but were not included in the 
final models because they did not meet the criteria to enter or to stay in the model: male gender, hsCRP. The following variables were forced into 
the model one at a time, but their inclusion did not significantly affect the relationship between coronary flow reserve ≤2.5 and variables of model 
1: current smoking, BMI, and total cholesterol. 
Table 2










Time from CFR 
(months) 
CFR 
1 44/M 26 MINOCA* Infliximab none / 5 2.3 
2 38/M 7 Type 1 MI^ Acitretin 70% LAD PTCA+DES 4 1.8 
3 45/M 6 MINOCA* Ustekinumab none / 77 2.0 
4 53/M 39 Type 1 MI^ Etanercept 90% RCA PTCA+DES 2 2.2 
5 46/M 23 Type 1 MI^ Adalimumab 
TCO Cx, 80% LAD, 
70% PDA 
CABG 100 2.3 
CABG, coronary artery bypass graft surgery; DES, drug eluting stent; LAD, left anterior descending coronary artery; MI, myocardial infarction; 
MINOCA, myocardial infarction with non-obstructive coronary arteries; PDA, posterior descending coronary artery; PTCA, percutaneous 
transluminal coronary angioplasty; RCA, right coronary artery; TCO total coronary occlusion. Other abbreviations as in Table 1. 
*MINOCA: MI with no angiographic obstructive coronary artery disease (≥50% diameter stenosis in a major epicardial vessel). 
^ Type 1 myocardial infarction: MI caused by atherothrombotic coronary artery disease and usually precipitated by atherosclerotic plaque 












Age, years 43±6 36±8 0.04 
Males, n (%) 5 (100) 117 (79) 0.3 
PASI 15 (7-31) 10 (3-15) 0.001 
Time elapsing since psoriasis diagnosis, years 13 (4-25) 6 (3-11) 0.04 
Presence of PsA, n (%) 2 (40) 48 (32) 0.4 
BMI, m
2
/Kg 27±5 26±4 0.7 
Hypertension, n (%) 4 (80) 21 (14) 0.002 
Family history of heart disease, n (%) 0 (0) 36(24) 0.2 
Current smoking, n (%) 0 (0) 54 (36) 0.1 
Previous smoking, n (%) 0 (0) 50 (33) 0.1 
SBP, mmHg 122±22 121±14 0.9 
DBP, mmHg 77±12 76±11 0.8 
Total cholesterol, mg/dL 200±18 194±43 0.8 
Triglycerides, mg/dL 94±65 110±62 0.7 
hsCRP, mg/L 2.1±0.2 2.4±0.7 0.1 
hDFV, cm/s 57 (48-61) 70 (60-80) 0.03 
CFR 2.1±0.2 3.1±0.7 0.001 
hDFV, hyperemic diastolic flow velocity. Other abbreviations as in Table 1. Data are presented as mean ± SD or as median
 
with first and third 
quartiles (Q1-Q3). 
Table 4
Table 5. Univariable prediction of cardiovascular events by logistic regression analysis 
 OR 95% CI p 
Age, years 1.14 0.99-1.3 0.04 
Males, n (%) 0.8 0.69-1.01 0.9 
PASI 1.2 1.1-1.32 0.02 
Time elapsing since psoriasis diagnosis, years 1.68 1.02-2.76 0.04 
Presence of PsA, n (%) 3.13 1.91-19.6 0.2 
BMI, m
2
/Kg 1.02 0.83-1.26 0.8 
Hypertension, n (%) 24 2.6-34 0.005 
Family history of heart disease, n (%) 1.26 0.13-11.7 0.8 
Current smoking, n (%) 0.81 0.62-1.31 0.9 
Previous smoking, n (%) 0.96 0.78-1.23 0.9 
SBP, mmHg 1.0 0.93-1.07 0.9 
DBP, mmHg 1.0 0.92-1.09 0.8 
Total cholesterol, mg/dL 1.01 0.99-1.04 0.2 
Triglycerides, mg/dL 1.0 0.98-1.02 0.8 
hsCRP, mg/L 1.8 1.3-2.14 0.2 
hDFV, cm/s 1.03 1.0-1.1 0.1 
CFR 7.81 1.93-31.2 0.004 
Abbreviations as in Table 1 and 4.  
Table 5
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